DHR
Danaher Corporation · Healthcare · Medical - Diagnostics & Research
Momentum-inputs (vergelijkbare managers):
breedte van houders +4.2% ·
aandelenstroom +2.3% ·
netto nieuwe posities +4.0%
— formule
Brede accumulatie — stijgende aandelen bij meer houders
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q4 2024
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q2 2026 | 190 | +7 | 438.00M | $83.49B | +10 | −2 |
| Q1 2026 | 185 | -2 | 440.89M | $83.51B | +5 | −8 |
| Q4 2025 | 186 | -1 | 467.58M | $107.03B | +2 | −2 |
| Q3 2025 | 30 | -1 | 269.80M | $53.47B | +1 | −3 |
| Q2 2025 | 29 | +2 | 237.37M | $46.89B | +3 | −1 |
| Q1 2025 | 24 | -1 | 116.89M | $23.96B | +1 | −2 |
| Q4 2024 | 25 | +1 | 111.55M | $25.60B | +1 | — |
| Q3 2024 | 23 | +1 | 81.67M | $22.69B | +2 | −1 |
| Q2 2024 | 22 | — | 81.37M | $20.32B | — | — |
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passief) | 27.38M | — | $6.29B | 0.2% | n/c | 1 | SEC ↗ |
| 2 | Wellington Management ✦ | 21.32M | -8.5% | $4.89B | 0.9% | ▼ Trim | 3 | SEC ↗ ×9 |
| 3 | T. Rowe Price ✦ | 18.98M | -7.3% | $4.36B | 0.5% | ▼ Trim | 3 | SEC ↗ ×2 |
| 4 | Geode Capital Management ✦ (passief) | 13.36M | +2.4% | $3.06B | 0.2% | ▲ Add | 3 | SEC ↗ ×2 |
| 5 | Norges Bank ✦ (passief) | 9.28M | +3.7% | $2.13B | 0.3% | ▲ Add | 3 | SEC ↗ |
| 6 | Capital World Investors ✦ | 6.36M | +32.7% | $1.46B | 0.2% | ▲ Add | 3 | SEC ↗ |
| 7 | Fisher Asset Management ✦ | 4.58M | +0.6% | $1.05B | 0.4% | ▲ Add | 3 | SEC ↗ |
| 8 | D. E. Shaw & Co. ✦ | 2.11M | +40977.5% | $485.42M | 0.6% | ▲ Add | 3 | SEC ↗ ×2 |
| 9 | Third Point ✦ | 1.90M | -2.6% | $436.14M | 5.9% | ▼ Trim | 3 | SEC ↗ |
| 10 | Point72 Asset Management ✦ | 1.35M | +462.0% | $309.56M | 0.9% | ▲ Add | 2 | SEC ↗ |
| 11 | Two Sigma Investments ✦ | 1.03M | +316.7% | $235.86M | 0.6% | ▲ Add | 2 | SEC ↗ |
| 12 | Arrowstreet Capital ✦ | 803.75K | +140.6% | $184.50M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 13 | Millennium Management ✦ | 632.99K | +27.8% | $145.30M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 14 | Citadel Advisors ✦ | 586.91K | -12.6% | $134.72M | 0.1% | ▼ Trim | 3 | SEC ↗ ×2 |
| 15 | Marshall Wace ✦ | 445.66K | -59.3% | $102.30M | 0.1% | ▼ Trim | 3 | SEC ↗ ×3 |
| 16 | Adage Capital Partners ✦ | 437.27K | -34.2% | $100.38M | 0.2% | ▼ Trim | 3 | SEC ↗ |
| 17 | AQR Capital Management ✦ | 376.91K | +4.3% | $86.52M | 0.1% | ▲ Add | 3 | SEC ↗ ×5 |
| 18 | Gates Foundation Trust ✦ | 373.00K | 0.0% | $85.62M | 0.2% | Held | 3 | SEC ↗ |
| 19 | Soros Fund Management ✦ | 130.47K | Nieuw | $29.95M | 0.8% | New | 1 | SEC ↗ |
| 20 | Gotham Asset Management ✦ | 57.04K | +29.0% | $13.09M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 21 | Harris Associates (Oakmark) ✦ | 17.67K | -6.6% | $4.06M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 22 | Dodge & Cox ✦ | 16.52K | 0.0% | $3.79M | 0.0% | Held | 3 | SEC ↗ |
| 23 | PRIMECAP Management ✦ | 12.40K | -61.2% | $2.85M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 24 | GAMCO Investors ✦ | 2.62K | -15.9% | $601,651 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 25 | Bridgewater Associates ✦ | 1.25K | -25.4% | $287,856 | 0.0% | ▼ Trim | 3 | SEC ↗ |
"Hun gewicht" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die beheerder — de overtuigingsmaatstaf. ✦ = gecureerde beheerder.
Nieuwe kopers
| Soros Fund Management | $29.95M | 0.8% |
Verlaten
| Geen bijgehouden uitstappen dit kwartaal. |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 2,147 houders, 548.39M aandelen, $97.77B gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Wat de gevolgde houders van dit effect verder het vaakst bezitten — aantallen gedeeld eigendom, geen fundamentele relaties.
Open-market aankopen (P)
Geen open-market insider-aankopen in ons dekkingsvenster.
Open-market verkopen (S)
Officer, Director · 11.31K aand · $2.46M
Officer, Director · 39.19K aand · $8.57M
Officer, Director · 7.75K aand · $1.70M
Toekenningen, uitoefeningen en belastinginhoudingen worden hier nooit meegeteld als aankopen of verkopen. Methodologie